Prostate Cancer Awareness Week, 1992: A summary of key findings

E. De Antoni, E. D. Crawford, N. N. Stone, D. S. Blum, E. R. Berger, Mario Eisenberger, S. R. Gambert, F. Staggers

Research output: Contribution to journalArticle

Abstract

Prostate Cancer Awareness Week was begun in 1989 to investigate whether men could be recruited to participate in free prostate cancer screening. Initially designed to raise public awareness of 'the ignored male disease', it has become the largest single cancer screening program in the United States. In 1992, more than 500,000 men were examined by digital rectal examination (DRE) and more than half of these also by measuring prostate-specific antigen (PSA). Although the populations examined have been generally better educated than the national average, predominantly white, and typically (> 40%) experiencing some symptom of prostate disease, adherence to annual prostate examinations remains low among successive cohorts of participants. Prostate cancers detected through this program exhibit a more favorable stage distribution than the national average. From 1989 through 1992, many cancers were detected by using the effective combination of DRE and PSA testing, which resulted in more stage A disease being diagnosed and fewer stage B, C, and D tumors. Data from 1992 suggest that increasing sophistication is possible with PSA test results, and age-specific PSA reference ranges have been developed.

Original languageEnglish (US)
Pages (from-to)448-457
Number of pages10
JournalClinical and Investigative Medicine
Volume16
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Digital Rectal Examination
Early Detection of Cancer
Prostate
Neoplasms
Reference Values
Population

Keywords

  • age-specific PSA reference ranges
  • digital rectal examination
  • prostate cancer screening
  • prostate-specific antigen (PSA)
  • risk factors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De Antoni, E., Crawford, E. D., Stone, N. N., Blum, D. S., Berger, E. R., Eisenberger, M., ... Staggers, F. (1993). Prostate Cancer Awareness Week, 1992: A summary of key findings. Clinical and Investigative Medicine, 16(6), 448-457.

Prostate Cancer Awareness Week, 1992 : A summary of key findings. / De Antoni, E.; Crawford, E. D.; Stone, N. N.; Blum, D. S.; Berger, E. R.; Eisenberger, Mario; Gambert, S. R.; Staggers, F.

In: Clinical and Investigative Medicine, Vol. 16, No. 6, 1993, p. 448-457.

Research output: Contribution to journalArticle

De Antoni, E, Crawford, ED, Stone, NN, Blum, DS, Berger, ER, Eisenberger, M, Gambert, SR & Staggers, F 1993, 'Prostate Cancer Awareness Week, 1992: A summary of key findings', Clinical and Investigative Medicine, vol. 16, no. 6, pp. 448-457.
De Antoni E, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger M et al. Prostate Cancer Awareness Week, 1992: A summary of key findings. Clinical and Investigative Medicine. 1993;16(6):448-457.
De Antoni, E. ; Crawford, E. D. ; Stone, N. N. ; Blum, D. S. ; Berger, E. R. ; Eisenberger, Mario ; Gambert, S. R. ; Staggers, F. / Prostate Cancer Awareness Week, 1992 : A summary of key findings. In: Clinical and Investigative Medicine. 1993 ; Vol. 16, No. 6. pp. 448-457.
@article{1e458e34c968495aaab993c32164e7a7,
title = "Prostate Cancer Awareness Week, 1992: A summary of key findings",
abstract = "Prostate Cancer Awareness Week was begun in 1989 to investigate whether men could be recruited to participate in free prostate cancer screening. Initially designed to raise public awareness of 'the ignored male disease', it has become the largest single cancer screening program in the United States. In 1992, more than 500,000 men were examined by digital rectal examination (DRE) and more than half of these also by measuring prostate-specific antigen (PSA). Although the populations examined have been generally better educated than the national average, predominantly white, and typically (> 40{\%}) experiencing some symptom of prostate disease, adherence to annual prostate examinations remains low among successive cohorts of participants. Prostate cancers detected through this program exhibit a more favorable stage distribution than the national average. From 1989 through 1992, many cancers were detected by using the effective combination of DRE and PSA testing, which resulted in more stage A disease being diagnosed and fewer stage B, C, and D tumors. Data from 1992 suggest that increasing sophistication is possible with PSA test results, and age-specific PSA reference ranges have been developed.",
keywords = "age-specific PSA reference ranges, digital rectal examination, prostate cancer screening, prostate-specific antigen (PSA), risk factors",
author = "{De Antoni}, E. and Crawford, {E. D.} and Stone, {N. N.} and Blum, {D. S.} and Berger, {E. R.} and Mario Eisenberger and Gambert, {S. R.} and F. Staggers",
year = "1993",
language = "English (US)",
volume = "16",
pages = "448--457",
journal = "Clinical and Investigative Medicine",
issn = "0147-958X",
publisher = "The Canadian Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Prostate Cancer Awareness Week, 1992

T2 - A summary of key findings

AU - De Antoni, E.

AU - Crawford, E. D.

AU - Stone, N. N.

AU - Blum, D. S.

AU - Berger, E. R.

AU - Eisenberger, Mario

AU - Gambert, S. R.

AU - Staggers, F.

PY - 1993

Y1 - 1993

N2 - Prostate Cancer Awareness Week was begun in 1989 to investigate whether men could be recruited to participate in free prostate cancer screening. Initially designed to raise public awareness of 'the ignored male disease', it has become the largest single cancer screening program in the United States. In 1992, more than 500,000 men were examined by digital rectal examination (DRE) and more than half of these also by measuring prostate-specific antigen (PSA). Although the populations examined have been generally better educated than the national average, predominantly white, and typically (> 40%) experiencing some symptom of prostate disease, adherence to annual prostate examinations remains low among successive cohorts of participants. Prostate cancers detected through this program exhibit a more favorable stage distribution than the national average. From 1989 through 1992, many cancers were detected by using the effective combination of DRE and PSA testing, which resulted in more stage A disease being diagnosed and fewer stage B, C, and D tumors. Data from 1992 suggest that increasing sophistication is possible with PSA test results, and age-specific PSA reference ranges have been developed.

AB - Prostate Cancer Awareness Week was begun in 1989 to investigate whether men could be recruited to participate in free prostate cancer screening. Initially designed to raise public awareness of 'the ignored male disease', it has become the largest single cancer screening program in the United States. In 1992, more than 500,000 men were examined by digital rectal examination (DRE) and more than half of these also by measuring prostate-specific antigen (PSA). Although the populations examined have been generally better educated than the national average, predominantly white, and typically (> 40%) experiencing some symptom of prostate disease, adherence to annual prostate examinations remains low among successive cohorts of participants. Prostate cancers detected through this program exhibit a more favorable stage distribution than the national average. From 1989 through 1992, many cancers were detected by using the effective combination of DRE and PSA testing, which resulted in more stage A disease being diagnosed and fewer stage B, C, and D tumors. Data from 1992 suggest that increasing sophistication is possible with PSA test results, and age-specific PSA reference ranges have been developed.

KW - age-specific PSA reference ranges

KW - digital rectal examination

KW - prostate cancer screening

KW - prostate-specific antigen (PSA)

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=0027817294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027817294&partnerID=8YFLogxK

M3 - Article

C2 - 7516833

AN - SCOPUS:0027817294

VL - 16

SP - 448

EP - 457

JO - Clinical and Investigative Medicine

JF - Clinical and Investigative Medicine

SN - 0147-958X

IS - 6

ER -